Trospium
- Generic Name
- Trospium
- Brand Names
- Trosec
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30NO3
- CAS Number
- 47608-32-2
- Unique Ingredient Identifier
- T4Y8ORK057
- Background
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
- Associated Conditions
- Overactive Bladder Syndrome (OABS)
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 406
- Registration Number
- NCT06585787
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
🇺🇸JY Research Institute Inc, Cutler Bay, Florida, United States
🇺🇸Chandler Clinical Trials, LLC, Chandler, Arizona, United States
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 173
- Registration Number
- NCT06572449
- Locations
- 🇺🇸
Local Institution - 0002, Los Alamitos, California, United States
🇺🇸Local Institution - 0004, Riverside, California, United States
🇺🇸Local Institution - 0006, Hollywood, Florida, United States
Gabapentin Versus Trospium Chloride for Prevention of a Catheter-related Bladder Discomfort Inside the ICU
- Conditions
- Catheter-related Bladder Discomfort (CRBD)
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT06346522
- Locations
- 🇪🇬
Ain Shams University-Faculty of Medicine, Cairo, Egypt
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 400
- Registration Number
- NCT06126224
- Locations
- 🇨🇳
Local Institution - 7007, Hefei, Anhui, China
🇨🇳Local Institution - 7009, Guangzhou, Guangdong, China
🇨🇳Local Institution - 7017, Hangzhou, Zhejiang, China
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 600
- Registration Number
- NCT05980949
- Locations
- 🇫🇷
Local Institution - 2513, Toulouse, France
🇷🇸Local Institution - 1-13JAX17Q, Gornja Toponica, Serbia
🇺🇸CCM Clinical Research Group, Miami, Florida, United States
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
- Conditions
- Accidental FallsUrinary Bladder, OveractiveUrinary Incontinence
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 48
- Registration Number
- NCT05880862
- Locations
- 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Karuna Therapeutics
- Target Recruit Count
- 380
- Registration Number
- NCT05511363
- Locations
- 🇺🇸
Asclepes Research, Encino, California, United States
🇺🇸Local Institution - 1031, Irvine, California, United States
🇺🇸Sunwise Clinical Research, LLC - IVY - PPDS, Lafayette, California, United States
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
- Conditions
- Urgency Urinary Incontinence
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Becky Clarkson
- Target Recruit Count
- 220
- Registration Number
- NCT04227184
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:
- Conditions
- Ureter StoneQuality of LifeUreter Obstruction
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 200
- Registration Number
- NCT03709992
- Locations
- 🇪🇬
Ahmed R EL-Nahas, Mansoura, Kuwait, Egypt
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.